CEO Ron Cohen (Acorda)

Acor­da of­floads man­u­fac­tur­ing op­er­a­tions to Catal­ent for $70M amid lat­est re­struc­tur­ing to keep the ship afloat

Just over a year af­ter the Supreme Court quashed any hopes Acor­da had of pro­tect­ing its once-lu­cra­tive mul­ti­ple scle­ro­sis drug Ampyra from cheap­er knock­offs, the New York biotech con­tin­ues to bleed cash. Now, as part of its third re­struc­tur­ing since 2017, the drug­mak­er is of­fload­ing one of its key as­sets.

As part of a sweep­ing over­haul Acor­da will sell its man­u­fac­tur­ing op­er­a­tions for In­bri­ja — an in­haled pow­der for­mu­la­tion of lev­odopa — to Catal­ent for $70 mil­lion in up­front cash that will save Acor­da an ad­di­tion­al $10 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.